390 related articles for article (PubMed ID: 19090343)
1. Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study.
Rendon M; Cardona LM; Bussear EW; Benitez AL; Colón LE; Johnson LA
Cutis; 2008 Nov; 82(5):372-8. PubMed ID: 19090343
[TBL] [Abstract][Full Text] [Related]
2. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.
Grimes PE; Bhawan J; Guevara IL; Colón LE; Johnson LA; Gottschalk RW; Pandya AG
J Am Acad Dermatol; 2010 Jun; 62(6):962-7. PubMed ID: 20398959
[TBL] [Abstract][Full Text] [Related]
3. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Monheit GD; Dreher F
J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.
Goldman MP; Gold MH; Palm MD; Colón LE; Preston N; Johnson LA; Gottschalk RW
Dermatol Surg; 2011 Feb; 37(2):224-33. PubMed ID: 21269349
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
[TBL] [Abstract][Full Text] [Related]
7. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
Torok H; Taylor S; Baumann L; Jones T; Wieder J; Lowe N; Jarret M; Rich P; Pariser D; Tschen E; Martin D; Menter A; Weiss J
J Drugs Dermatol; 2005; 4(5):592-7. PubMed ID: 16167418
[TBL] [Abstract][Full Text] [Related]
8. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
[TBL] [Abstract][Full Text] [Related]
9. Comparative Evaluation of Efficacy and Tolerability of Glycolic Acid, Salicylic Mandelic Acid, and Phytic Acid Combination Peels in Melasma.
Sarkar R; Garg V; Bansal S; Sethi S; Gupta C
Dermatol Surg; 2016 Mar; 42(3):384-91. PubMed ID: 26859648
[TBL] [Abstract][Full Text] [Related]
10. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
Basit A; Rahman A; Uddin R
J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
[TBL] [Abstract][Full Text] [Related]
11. Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-standing clinical severity.
Arellano I; Cestari T; Ocampo-Candiani J; Azulay-Abulafia L; Bezerra Trindade Neto P; Hexsel D; Machado-Pinto J; Muñoz H; Rivitti-Machado MC; Sittart JA; Trindade de Almeida AR; Rego V; Paliargues F; Marques-Hassun K
J Eur Acad Dermatol Venereol; 2012 May; 26(5):611-8. PubMed ID: 21623930
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma.
Erbil H; Sezer E; Taştan B; Arca E; Kurumlu Z
J Dermatol; 2007 Jan; 34(1):25-30. PubMed ID: 17204097
[TBL] [Abstract][Full Text] [Related]
13. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study.
Sarkar R; Kaur C; Bhalla M; Kanwar AJ
Dermatol Surg; 2002 Sep; 28(9):828-32; discussion 832. PubMed ID: 12269877
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels.
Garg VK; Sarkar R; Agarwal R
Dermatol Surg; 2008 Aug; 34(8):1032-9; discussion 1340. PubMed ID: 18430172
[TBL] [Abstract][Full Text] [Related]
15. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life.
Dayal S; Sahu P; Dua R
J Cosmet Dermatol; 2017 Mar; 16(1):35-42. PubMed ID: 27500896
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
[TBL] [Abstract][Full Text] [Related]
17. Community-based trial of a triple-combination agent for the treatment of facial melasma.
Grimes P; Kelly AP; Torok H; Willis I
Cutis; 2006 Mar; 77(3):177-84. PubMed ID: 16610738
[TBL] [Abstract][Full Text] [Related]
18. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
Grimes PE
Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States.
Alikhan A; Daly M; Wu J; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2010 Sep; 21(5):276-81. PubMed ID: 20055711
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of a novel formulation in the treatment of melasma.
Guevara IL; Werlinger KD; Pandya AG
J Drugs Dermatol; 2010 Mar; 9(3):215-8. PubMed ID: 20232581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
